Kashiv BioSciences, LLC (“Kashiv”) announces that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”). This acquisition combines Kashiv’s extensive expertise in the development and manufacturing of biosimilars with Amneal’s scale and commercialization capabilities. Kashiv is headquartered in Piscataway, New Jersey with operations in the U.S. and India. Amneal is headquartered in Bridgewater, New Jersey, and is a leading biopharmaceutical company with one of the largest affordable medicine businesses in the U.S.
Read the full article: Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader //
Source: https://www.businesswire.com/news/home/20260421283753/en/Kashiv-BioSciences-Agrees-to-Be-Acquired-by-Amneal-Pharmaceuticals-to-Create-a-Fully-Integrated-Global-Biosimilar-Leader